Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III/IV Randomised Open-label Study and Comparison of the Immunogenicity and Safety of a Single Adolescent Booster Dose of a Meningococcal Group C Conjugate-containing Booster Vaccine (Meningitec™, OR NeisVac-C™ , OR Menitorix™), When Given Concurrently With an Acellular Pertussis-containing Booster Vaccine (Repevax™ or IPV-Boostrix™)

NCT02526394 is registered in ClinicalTrials.gov with Public Health England as lead sponsor.

NCT NCT02526394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02526394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III/IV Randomised Open-label Study and Comparison of the Immunogenicity and Safety of a Single Adolescent Booster Dose of a Meningococcal Group C Conjugate-containing Booster Vaccine (Meningitec™, OR NeisVac-C™ , OR Menitorix™), When Given Concurrently With an Acellular Pertussis-containing Booster Vaccine (Repevax™ or IPV-Boostrix™)
Lead sponsor
Public Health England
Phase
Phase 4
Overall status
Completed
Start date
September 30, 2013
Completion date
March 31, 2017
Enrollment
400 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

immunization, meningitis, pertussis, preventive immunization; meningitis